N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors

US9334274B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• James D. Rodgers · Landenberg, US
• Stacey Shepard · Wilmington, US
• Argyrios G. Arvanitis · Kennett Square, US
• Haisheng Wang · Hockessin, US
• Louis Storace · Middletown, US
• Beverly Folmer · Hockessin, US
• Wenyu Zhu · Wilmington, US
• Joseph Glenn · Sicklerville, US
• Lixin Shao · Wilmington, US

Key dates

• Filing date: Apr 11, 2014
• Grant date: May 10, 2016
• Expiry date: Apr 11, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I:which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.